Population studies show worrisome trends towards earlier breast development, difficulty in breastfeeding, and increasing rates of breast cancer in young women. Multiple epidemiological studies have linked these outcomes with chemical exposures, and experimental studies have shown that many of these chemicals generate similar effects in rodents, often by disrupting hormonal regulation. These endocrine-disrupting chemicals (EDCs) can alter the progression of mammary gland (MG) development, impair the ability to nourish offspring via lactation, increase mammary tissue density, and increase the propensity to develop cancer. However, current toxicological approaches to measuring the effects of chemical exposures on the MG are often inadequate to detect these effects, impairing our ability to identify exposures harmful to the breast and limiting opportunities for prevention. This paper describes key adverse outcomes for the MG, including impaired lactation, altered pubertal development, altered morphology (such as increased mammographic density), and cancer. It also summarizes evidence from humans and rodent models for exposures associated with these effects. We also review current toxicological practices for evaluating MG effects, highlight limitations of current methods, summarize debates related to how effects are interpreted in risk assessment, and make recommendations to strengthen assessment approaches. Increasing the rigor of MG assessment would improve our ability to identify chemicals of concern, regulate those chemicals based on their effects, and prevent exposures and associated adverse health effects.
10 June 2026 in Cancer Epidemiology, Biomarkers & Prevention
Background: Depression is a leading global health burden and has been linked to chronic diseases, including cancer. Chronic stress may promote colorectal carcinogenesis via hormonal, immune, and metabolic abnormalities. Evidence for the association between depression and colorectal cancer is inconsistent, and data on colorectal polyps are limited. Methods: We prospectively followed 91,383 women from the Nurses’ Health Study II (1993–2019) for colorectal cancer analyses, and 62,237 women (1993–2017) for adenoma and serrated polyp analyses. Depression was defined as a Mental Health Index-5 score ≤52, antidepressant use, or physician-diagnosed depression. Multivariable Cox proportional hazards models estimated hazard ratios (HR) for colorectal cancer, whereas logistic regression estimated odds ratios (OR) for adenomas and serrated polyps. Results: Over 2.36 million person-years of follow-up, 474 colorectal cancer cases were documented. Depression was modestly associated with lower risk of colorectal cancer [HR = 0.76; 95% confidence interval (CI), 0.59–0.97] and colon cancer but not rectal cancer. Among 62,237 women undergoing lower endoscopy over 24 years, 4,104 conventional adenomas and 4,563 serrated polyps were documented. Depression was modestly inversely associated with overall and large conventional adenomas (OR = 0.76; 95% CI, 0.63–0.92). No consistent association was observed with serrated polyps in primary models, although some sensitivity analyses suggested possible positive associations. Conclusions: Depression was inversely associated with colorectal cancer and large conventional adenomas. Associations with serrated polyps were not evident in primary models but varied across sensitivity analyses, requiring further study. Impact: These findings suggest potential differences across colorectal neoplastic pathways, indicating that the relationship between depression and colorectal carcinogenesis may be more complex than previously appreciated.
Supplementary Table S17 shows sensitivity analyses of depression defined by depressive symptoms (MHI-5 score or physician-diagnosed depression) in relation to colorectal cancer precursors.
Supplementary Table S9 shows sensitivity analyses of colorectal cancer precursors risk with alternative dietary adjustment using red and processed meat intake.